This post was originally published on this site
Strong sales of blockbuster drugs Keytruda and Gardasil helped Merck & Co. Inc. post better-than-expected first-quarter results on Thursday, despite plunging sales of its COVID-19 antiviral treatment.
The Rahway, N.J., based pharmaceutical giant MRK reported net income of $2.821 billion, or $1.11 per share, for the first quarter, down from $4.31 billion, or $1.70 per share, a year earlier. Adjusted per-share earnings of $1.40 beat the $1.32 FactSet consensus.
Sales…
